Scientific Advisory Board
Lisa A. Carey, MD
Dr. Lisa A. Carey is the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research in the Department of Medicine at the University of North Carolina (UNC). She received her medical degree from the Johns Hopkins University School of Medicine where she remained for her residency in Internal Medicine followed by a fellowship in Medical Oncology and an advanced degree in Clinical Investigations. Dr. Carey joined the UNC faculty and Lineberger Comprehensive Cancer Center in 1998. Currently she is the Chief of the Division of Hematology and Oncology and Physician-in-Chief of the North Carolina Cancer Hospital. Dr. Carey has a longstanding research interest in the clinical application of laboratory findings in breast cancer. She designs and leads clinical trials of novel drugs and approaches, and is a close collaborator with several laboratory investigators and epidemiologists. In addition, Dr. Carey sits on numerous scientific advisory boards, She has served in many roles for the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research(AACR) and the NCI. She was awarded the Doris Duke Clinician Scientist Award in 1999, a Career Development Award from the National Cancer Institute (NCI) in 2000, was inducted into the Johns Hopkins Society of Scholars in 2008, was awarded the NCI Director's Service Award in 2011, and was named co-chair of the Alliance National Cooperate Group Breast Committee in 2016.
Stephen Frye, PhD
Dr. Stephen Frye is currently a Fred Eshelman Distinguished Professor and the Director of the Center for Integrative Chemical Biology and Drug Discovery (CICBDD) at the University of North Carolina at Chapel Hill (UNC). He is also co-director of the Molecular Therapeutics program in the Lineberger Comprehensive Cancer Center and the lead principal investigator for the North Carolina Comprehensive Chemical Biology Center, a UNC-based, National Cancer Institute (NCI) designated center that engages in oncology drug discovery. Prior to joining UNC to create the CICBDD in 2007, Dr. Frye was the world-wide vice president of Discovery Medicinal Chemistry (DMC) at GlaxoSmithKline (GSK). Dr. Frye led DMC for seven years, overseeing five departments and more than 200 chemists in the U.S. and U.K. developing global target-class chemical science for GSK. During his 20-year career at GSK, the teams/departments led by Dr. Frye successfully developed three FDA approved drugs: Avodart, a dual 5alpha-reductase inhibitor for treatment of benign prostatic hyperplasia, Tykerb, a dual erbB2/EGFR inhibitor for the treatment of metastatic breast cancer, and Pazopanib, a multi-targeted receptor tyrosine kinase inhibitor for the treatment of renal cell carcinoma and soft tissue sarcoma.As director of the Center for Integrative Chemical Biology and Drug Discovery at UNC, Dr. Frye plays a key role in translational research through collaborative drug discovery projects with other UNC faculty. In addition, his Center has initiated a program in the area of chemical biology of chromatin regulation with an emphasis on methyl-lysine reading domains. The first IND approved compound discovered in the Center, will enter clinical trials in 2018.
Jian Jin, PhD
Dr. Jian Jin is currently a Professor in the Departments of Pharmacological Sciences and Oncological Sciences, and the Director of the Center for Chemical Biology and Drug Discovery at Icahn School of Medicine at Mount Sinai (Mount Sinai). Dr. Jin is a medicinal chemistry expert with more than 20 years of experience in small-molecule drug discovery in both academia and industry. Prior to joining Mount Sinai in 2014, Dr. Jin was an Associate Professor at the University of North Carolina at Chapel Hill (UNC). He had also served as an Associate Director of medicinal chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC from 2008 to 2014. Before his academic career at Mount Sinai and UNC, Dr. Jin had more than 10 years of industry experience in drug discovery at GlaxoSmithKline. For last several years, Dr. Jin’s lab has discovered multiple first-in-class small molecules that selectively degrade target proteins. These novel NCEs are potent, selective, bioavailable and efficacious in vivo.
Peter Jackson, PhD
Dr. Jackson is a Professor of Microbiology and Immunology (Baxter Labs) and of Pathology at Stanford. He received a BA in Mathematics and Economics from Yale College before pursuing graduate work in Chemical Physics at the University of Chicago and receiving a PhD in Biophysics from Harvard University, completing his thesis on tyrosine kinase signaling with David Baltimore at MIT’s Whitehead Institute. Following postdoctoral work at UCSF with Mark Kirschner, studying the cell cycle, Dr. Jackson joined the faculty at Stanford in 1996. His laboratory studies focus on the biochemical and cell biological mechanisms controlling cell division, signaling and cancer, using proteomics and advanced imaging techniques. He has made a broad set of discoveries related to regulatory complexes and signaling in the cell cycle, ubiquitin-dependent proteolysis, cancer, signaling within the primary cilium and the link between cilia and human genetic diseases. Dr. Jackson spent from 2005 to 2013 at Genentech, where he was a Director and Staff Scientist focused on the discovery and validation of new targets for cancer chemotherapy. He is currently focused on understanding core mechanisms driving differentiation, especially in the context of ciliary signaling and using protein networks to find new core cancer driver pathways and explanations for unexplained human genetic diseases.
Yue Xiong, PhD
Dr. Xiong finished his undergraduate at Fudan University in 1982 and Ph.D from University of Rochester in 1989. After completing a Ph.D. Postdoctoral fellowship at Cold Spring Harbor Lab, from 1993 up to now, Dr. Xiong joined Department of Biochemistry & Biophysics at University of North Carolina at Chapel Hill as a William R. Kenan Professor. He was awarded Pew Scholar Award (1995), American Cancer Society Junior Faculty Research Award (1995), AACR-Gertrude B. Elion Cancer Research Awards (1999), UNC Hettleman Award for Scholarly Achievement (1999), UNC Battle Distinguished Cancer Research Award (2011), Elected Fellow, American Association for Advancement of Science (2012). To date, Dr. Xiong has published more than 160 research papers in peer-reviewed publication and granted two US patents.